Evaluation of an aminotetraline, CP 14.368, as an antidepressant.
D015057:1-Naphthylamine / Q000031:analogs & derivatives; D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000097:blood / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D004562:Electrocardiography; D005069:Evaluation Studies as Topic; D006801:Humans; D008744:Methylamines / Q000009:adverse effects / Q000097:blood / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D009281:Naphthalenes / Q000009:adverse effects / Q000097:blood / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000928:Antidepressive Agents; D008744:Methylamines; D009281:Naphthalenes; D015057:1-Naphthylamine; C001048:lometraline